HK1218079A1 - 亞硝酸鹽的藥物製劑及其用途 - Google Patents

亞硝酸鹽的藥物製劑及其用途

Info

Publication number
HK1218079A1
HK1218079A1 HK16106249.8A HK16106249A HK1218079A1 HK 1218079 A1 HK1218079 A1 HK 1218079A1 HK 16106249 A HK16106249 A HK 16106249A HK 1218079 A1 HK1218079 A1 HK 1218079A1
Authority
HK
Hong Kong
Prior art keywords
nitrite
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Application number
HK16106249.8A
Other languages
English (en)
Inventor
Christopher Kevil
Kyle Chan
Amol Soin
Original Assignee
Theravasc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravasc Inc filed Critical Theravasc Inc
Publication of HK1218079A1 publication Critical patent/HK1218079A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16106249.8A 2013-02-20 2016-06-02 亞硝酸鹽的藥物製劑及其用途 HK1218079A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361767017P 2013-02-20 2013-02-20
PCT/US2014/017432 WO2014130691A2 (en) 2013-02-20 2014-02-20 Pharmaceutical formulations of nitrite and uses thereof

Publications (1)

Publication Number Publication Date
HK1218079A1 true HK1218079A1 (zh) 2017-02-03

Family

ID=51391970

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106249.8A HK1218079A1 (zh) 2013-02-20 2016-06-02 亞硝酸鹽的藥物製劑及其用途

Country Status (12)

Country Link
US (2) US9561249B2 (zh)
EP (1) EP2958573B1 (zh)
JP (1) JP2016509030A (zh)
KR (1) KR102472588B1 (zh)
CN (1) CN105358160A (zh)
AU (1) AU2014218916A1 (zh)
BR (1) BR112015019802A2 (zh)
CA (1) CA2899602C (zh)
DK (1) DK2958573T3 (zh)
ES (1) ES2741146T3 (zh)
HK (1) HK1218079A1 (zh)
WO (1) WO2014130691A2 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009065142A2 (en) * 2007-11-15 2009-05-22 Biomedical Research Foundation Of Northwest Louisiana Use of nitrite salts in chronic ischemia
BR112015019802A2 (pt) * 2013-02-20 2017-07-18 Theravasc Inc formulações farmacêuticas de nitrito e usos das mesmas
GB201602959D0 (en) 2016-02-19 2016-04-06 Isis Innovation Use of cerebral nitric oxide donors in the assessment of the extent of brain dyfunction following injury
CA3026639A1 (en) * 2016-06-06 2017-12-14 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Uses of inorganic nitrite for increasing nerve conduction velocity
US12023173B2 (en) * 2017-07-14 2024-07-02 Pamela, Inc. Pain classification and momentary-pain determination using sparse modeling
CN108785106B (zh) * 2018-06-05 2021-03-16 中国科学院上海硅酸盐研究所 一种胶状含银磷酸钙纳米复合材料及其制备方法和应用
WO2020141546A1 (en) 2019-01-02 2020-07-09 Celagenex Research (India) Pvt. Ltd. Synergistic nutritional compositions for pain management
AU2020376801A1 (en) * 2019-10-28 2022-06-09 Acadia Pharmaceuticals Inc. Methods and compositions for treatment of Rett syndrome

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650484A (en) 1983-02-03 1987-03-17 Alza Corporation Method for treating ischemic conditions
IE64726B1 (en) 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
US5122384A (en) 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5278192A (en) 1992-07-02 1994-01-11 The Research Foundation Of State University Of New York Method of vasodilator therapy for treating a patient with a condition
US6709681B2 (en) 1995-02-17 2004-03-23 Aberdeen University Acidified nitrite as an antimicrobial agent
US20110196039A9 (en) 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US5648101A (en) * 1994-11-14 1997-07-15 Tawashi; Rashad Drug delivery of nitric oxide
US5692500A (en) * 1995-01-09 1997-12-02 Gaston-Johansson; Fannie Pain measurement and recording tool and method
US5770645A (en) 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US5994444A (en) 1997-10-16 1999-11-30 Medtronic, Inc. Polymeric material that releases nitric oxide
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
US7015876B1 (en) 1998-06-03 2006-03-21 Lear Corporation Heads-up display with improved contrast
AU4995699A (en) 1998-07-14 2000-02-07 Paracelsian, Inc. Method for identifying and confirming consistent bio-functionality of natural compositions
CA2360655C (en) 1999-01-29 2007-03-20 Losan Pharma Gmbh Pharmaceutical compositions
GB9905425D0 (en) 1999-03-09 1999-05-05 Queen Mary & Westfield College Pharmaceutical composition
GB0119011D0 (en) 2001-08-03 2001-09-26 Univ Aberdeen Treatment of nail infections
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
CA2479098A1 (en) * 2002-03-20 2003-09-25 Maree Therese Smith Methods and compositions comprising nitric oxide donors and opioid analgesics
CA2379211A1 (fr) 2002-03-28 2003-09-28 Institut De Cardiologie De Montreal Utilisation du bleu de methylene pour renverser la reaction hemodynamique exageree induite par la combinaison d'un derive nitre et du sildenafil ou d'une molecule de meme classe (inhibiteur de la phosphodiesterase)
DE602004008927T2 (de) 2003-07-09 2008-06-05 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Verwendung von nitritsalzen zur behandlung von kardiovaskulären erkrankungen
CA2536173A1 (en) 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
US20050113409A1 (en) 2003-09-03 2005-05-26 Pharmacia Corporation Method for the prevention or treatment of pain, inflammation and inflammation-related disorders with a Cox-2 selective inhibitor in combination with a nitric oxide-donating agent and compositions therewith
US7362274B1 (en) 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
US20060083824A1 (en) 2004-10-20 2006-04-20 Pbm Products Llc Nutritional supplements for glucose intolerant individuals
US20120225053A1 (en) 2005-05-24 2012-09-06 Slavik Dushenkov Compositions and methods for the prevention and treatment of conditions associated with inflamation
GB0607402D0 (en) 2006-04-12 2006-05-24 Barts & London Nhs Trust Therapeutic composition and use
US8333997B2 (en) 2006-06-21 2012-12-18 Albert Einstein College Of Medicine Of Yeshiva University Compositions for sustained release of nitric oxide, methods of preparing same and uses thereof
US10406118B2 (en) 2007-02-26 2019-09-10 Jon Lundberg Use of nitrites and nitrates and compositions containing these
EP3159000A1 (en) 2007-02-26 2017-04-26 HeartBeet Ltd. Performance enhancing composition
WO2008153762A2 (en) 2007-05-25 2008-12-18 N30 Pharmaceuticals, Llc S-nitrosothiol formulations and storage systems
WO2009065142A2 (en) * 2007-11-15 2009-05-22 Biomedical Research Foundation Of Northwest Louisiana Use of nitrite salts in chronic ischemia
AU2008345034A1 (en) 2007-12-27 2009-07-09 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide - donating compounds and uses thereof
WO2010036236A1 (en) 2008-09-23 2010-04-01 Baker Hughes Incorporated Anchor assembly
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
WO2010147742A2 (en) * 2009-06-18 2010-12-23 Theravasc Inc. Use of nitrite salts in treating tissue damage
ES2633618T3 (es) * 2009-10-14 2017-09-22 Theravasc Inc. Formulaciones farmacéuticas de nitrito y sus usos
US20130209584A1 (en) * 2009-10-14 2013-08-15 Theravasc Inc. Pharmaceutical formulations of nitrite and uses thereof
ES2553745T3 (es) * 2010-10-21 2015-12-11 Kipax Ab Dispositivo de suministro tópico dérmico para suministro de óxido nítrico
US20140127329A1 (en) 2011-03-31 2014-05-08 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use of nitrites for the treatment of cerebral amyloid angiopathy, age associated dementia, and cognitive decline
WO2012142413A2 (en) 2011-04-14 2012-10-18 Theravasc Inc. Nitrite compositions and uses thereof
BR112015019802A2 (pt) * 2013-02-20 2017-07-18 Theravasc Inc formulações farmacêuticas de nitrito e usos das mesmas

Also Published As

Publication number Publication date
BR112015019802A2 (pt) 2017-07-18
AU2014218916A1 (en) 2015-09-03
WO2014130691A2 (en) 2014-08-28
KR20150120479A (ko) 2015-10-27
KR102472588B1 (ko) 2022-12-01
CN105358160A (zh) 2016-02-24
US20170143759A1 (en) 2017-05-25
DK2958573T3 (da) 2019-08-05
JP2016509030A (ja) 2016-03-24
CA2899602A1 (en) 2014-08-28
US9561249B2 (en) 2017-02-07
WO2014130691A3 (en) 2014-10-16
CA2899602C (en) 2024-01-30
EP2958573A4 (en) 2016-10-19
EP2958573B1 (en) 2019-05-08
US20150196588A1 (en) 2015-07-16
ES2741146T3 (es) 2020-02-10
EP2958573A2 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
HK1222122A1 (zh) 選擇性藥物遞送組合物及使用方法
ZA201602510B (en) Strigolactone formulations and uses thereof
HK1221416A1 (zh) 氧雜雙環庚烷和氧雜雙環庚烯的配製品
IL265876A (en) Preparations that include 15-ohepa and methods of using them
EP2964235A4 (en) ANTIMICROBIAL-ANTIBIOFILM COMPOSITIONS AND METHODS OF USE
EP2981611A4 (en) ANTIBIOTICUM PROTOCOLS AND PHARMACEUTICAL FORMULATIONS AND TREATMENT METHODS THEREWITH
IL243608A0 (en) Substances with antiviral activity, preparations containing them and their uses
RS58758B9 (sr) Vatrostalna smesa i njena upotreba
HK1220920A1 (zh) 治療性組合物和其用途
HK1218079A1 (zh) 亞硝酸鹽的藥物製劑及其用途
HK1218855A1 (zh) 干粉製劑及使用方法
HK1215859A1 (zh) 包含蜂膠提取物的治療性組合物和其用途
SG11201507389RA (en) Integration of hydro-dechlorination and hydro-regeneration
HK1219691A1 (zh) 醫藥組成物及其用途
EP2994755A4 (en) Therapeutic and imaging compositions and uses thereof
PL3228313T3 (pl) Postacie dawkowania i zastosowania terapeutyczne L-4-chlorokineureniny
HK1204916A1 (zh) 淫羊藿苷元的醫藥用途
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
HK1217670A1 (zh) 調配物、其製造方法和用途
EP3052475A4 (en) Pharmaceutical use of 3-benzylsulfonylpropionitrile
AU2013901834A0 (en) Formulations and Therapeutic Uses Thereof
GB201207064D0 (en) Pharmaceutical compositions comprising 15-hetre and methods of using the same
GB201300628D0 (en) Compositions comprising 15-OHEPA and methods of using the same